Australia markets closed

23andMe Holding Co. (ME)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.5000-0.1500 (-3.23%)
At close: 04:00PM EST
4.3000 -0.20 (-4.44%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous close4.6500
Open4.6350
Bid4.3000 x 4000
Ask4.4000 x 800
Day's range4.4000 - 4.6700
52-week range4.4000 - 18.1600
Volume2,858,039
Avg. volume3,058,717
Market cap2.076B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.2120
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est11.50
  • GlobeNewswire

    23andMe Announces Extension of GSK Collaboration and Update on Joint Immuno-oncology Program

    GSK extends exclusive target discovery period of collaboration for a fifth year to discover and validate novel drug targets using 23andMe’s proprietary genetic and health survey database 23andMe elects for royalty option as GSK advances immuno-oncology antibody collaboration program targeting CD96 into development Company will discuss at its R&D Day event today at 8:00 a.m. Pacific Time SUNNYVALE, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading c

  • GlobeNewswire

    23andMe Receives FDA Clearance for Direct-to-Consumer Genetic Test on a Hereditary Prostate Cancer Marker

    The clearance allows 23andMe to report on the G84E mutation in the HOXB13 gene, clinically shown to significantly increase the risk of developing prostate cancer in men with the mutationSUNNYVALE, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today received FDA clearance for a genetic health risk report on a hereditary prostate cancer marker. This is the Company’s third cancer risk report clearance, follo

  • GlobeNewswire

    23andMe Initiates Phase 1 Clinical Trial for First Wholly-Owned Immuno-oncology Antibody for Patients with Solid Tumors

    23ME-00610 targets CD200R1, an important regulator of T cells and myeloid cells CD200R1 was identified as a promising immuno-oncology target through 23andMe’s proprietary genetic and health survey database Company will host a virtual R&D Day event on January 18, 2022 SUNNYVALE, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced the first participant has been dosed in a Phase 1 clinical trial ev